Andere talen Imunon, Inc.

Aandelen

IMNN

US15117N6022

Beurs gesloten - Nasdaq Andere beurzen 21:56:16 30-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,31 ^USD	-3,31%		-1,50%	+92,65%

18/04	Imunon, Inc. Aanvraag goedgekeurd om te beginnen met testen op mensen van IMNN-101	CI
01/04	IMUNON, INC. : Een koopadvies van HC Wainwright	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Imunon Receives FDA Approval to Start Phase 1 Trial of COVID-19 Booster Vaccine	18/04
Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine	18/04
IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101	18/04
Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101	18/04
IMUNON Reports Compliance with Nasdaq Listing Requirements	11/04
Top Midday Gainers	28/03
Imunon, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
IMUNON Reports 2023 Financial Results and Provides Business Update	28/03
North American Morning Briefing : Stocks Set for -2-	28/03
IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses	25/03
IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024	21/03
IMUNON Files IND Application to Begin Human Testing of IMNN-101	13/03
Imunon, Inc. Files Ind Application to Begin Human Testing of Imnn-101	13/03
IMUNON Names Executive Chairman as Temporary Head Following Resignation of CEO Corinne Le Goff	13/03
IMUNON Announces Leadership Change	12/03
Imunon, Inc. Announces Executive Changes	12/03
Imunon, Inc. Announces Resignation of Corinne Le Goff as Chief Executive Officer, Effective March 15, 2024	12/03
Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5	29/02
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer	27/02
IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine	22/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Imunon, Inc.

Aandelen

IMNN

US15117N6022

Andere talen

Filters